Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited uses 838 IPv4 addresses in 13 ranges, by the registry records IP Company reads.
Who routes its space
The networks announcing its IPv4, by the addresses each announces.
- AS9941 Ranbaxy Laboratories Limited512 · 61.10%
- AS32754 Sun Pharmaceutical Industries Inc.256 · 30.55%
- AS9583 Sify Limited18 · 2.15%
- AS9498 BHARTI Airtel Ltd.16 · 1.91%
- AS209 CenturyLink Communications, LLC8 · 0.95%
- AS15895 "Kyivstar" PJSC8 · 0.95%
- AS4755 TATA Communications formerly VSNL is Leading ISP4 · 0.48%
Where its space is
Its IPv4 that IP Geolocation places, by country. A /24 counts for the company using most of it.
- India512 · 66.67%
- United States256 · 33.33%
Networks it operates
The autonomous systems registered under its domain, by the IPv4 each announces anywhere.
What the databases see
Addresses each address-keyed database holds in its IPv4, as a share of it, with the largest providers. A /24 counts for the company using most of it; counts overlap.
- 0.36%
- Thordata0.12%
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- 0.36%
Its address ranges
Its largest IPv4 ranges, then its IPv6 ones, as IP Company draws them, a CIDR a row, with the network announcing each.
| RANGE | IPV4 | ORIGIN |
|---|---|---|
| 202.62.116.0/23 | 512 | AS9941 |
| 67.132.78.0/24 | 256 | AS32754 |
| 203.101.82.144/28 | 16 | AS9498 |
| 124.30.152.40/29 | 8 | AS9583 |
| 124.30.152.48/30 | 4 | AS9583 |
| 124.30.6.132/30 | 4 | |
| 124.30.6.136/29 | 8 | |
| 212.109.58.64/29 | 8 | AS15895 |
| 65.119.192.0/29 | 8 | AS209 |
| 124.30.53.88/30 | 4 | AS9583 |
| 221.134.68.232/30 | 4 | |
| 203.200.86.52/31 | 2 | AS4755 |
| 210.210.7.81/32 | 1 | AS9583 |
| 210.210.7.82/32 | 1 | AS9583 |
| 202.54.57.29/32 | 1 | AS4755 |
| 202.54.57.55/32 | 1 | AS4755 |
Names it registers under
The holder names its registry records give, by the IPv4 under each.
- Ranbaxy Laboratories Limited518 · 61.81%
- Ranbaxy Pharmaceuticals, Inc.256 · 30.55%
- RANBAXY LABORATORIES LIMITED32 · 3.82%
- Ranbaxy Laboratories24 · 2.86%
- RANBAXY INC8 · 0.95%
Test the real build first.
An evaluation license puts a full current build in your hands, with no sampling, so you can measure it against your own traffic before anyone talks about terms.